The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues

Journal of Biomedical Science

Volumn 19, Issue 1, 2012, Pages

  Zupan, Janja ^a   Komadina, Radko ^b   Marc, Janja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b General Hospital Celje   (Slovenia)

Author keywords

3integrin; Cathepsin K; Interferons; Interleukins; OSCAR; TGF 1; TNF

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BETA1 INTERFERON; CATHEPSIN K; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MEMBRANE PROTEIN; OSTEOCLAST ASSOCIATED IMMUNOGLOBULIN LIKE RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE RECEPTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN;

AGED; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HIP ARTHROPLASTY; HUMAN; HUMAN TISSUE; MALE; OSTEOARTHRITIS; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ARTHROPLASTY; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; METHODOLOGY; OSTEOCLAST;

AGED; ARTHROPLASTY; BONE DENSITY; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MALE; OSTEOARTHRITIS; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOKINE;

EID: 84857615261     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-19-28     Document Type: Article

References (38)

1. Osteoimmunology: cytokines and the skeletal system. Lee SH, Kim TS, Choi Y, Lorenzo J, BMB Rep 2008 41 7 495 510 10.5483/BMBRep.2008.41.7.495 18682033
2. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN, Pacifici R, J Clin Invest 2007 117 1 122 132 10.1172/JCI30074 17173138 (Pubitemid 46048459)
3. Inflammaging: The driving force in osteoporosis? Lencel P, Magne D, Med Hypotheses 2010 76 3 317 321 20961694
4. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB, Arthritis Rheum 2010 62 3 647 657 10.1002/art.27290 20187160
5. Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women. Pino AM, Rios S, Astudillo P, Fernandez M, Figueroa P, Seitz G, Rodriguez JP, J Bone Miner Res 2010 25 3 492 498 10.1359/jbmr.090802 19653807
6. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, McCracken R, Avioli LV, Proc Natl Acad Sci USA 1991 88 12 5134 5138 10.1073/pnas.88.12.5134 2052592 (Pubitemid 21914698)
7. Changes in proinflammatory cytokine activity after menopause. Pfeilschifter J, Koditz R, Pfohl M, Schatz H, Endocr Rev 2002 23 1 90 119 10.1210/er.23.1.90 11844745 (Pubitemid 34185307)
8. Estrogen deficiency and bone loss: an inflammatory tale. Weitzmann MN, Pacifici R, J Clin Invest 2006 116 5 1186 1194 10.1172/JCI28550 16670759
9. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. Cauley JA, Danielson ME, Boudreau RM, Forrest KY, Zmuda JM, Pahor M, Tylavsky FA, Cummings SR, Harris TB, Newman AB, J Bone Miner Res 2007 22 7 1088 1095 10.1359/jbmr.070409 17419681 (Pubitemid 351339731)
10. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R, Pfeilschifter J, J Clin Endocrinol Metab 2001 86 5 2032 2042 10.1210/jc.86.5.2032 11344203 (Pubitemid 32472916)
11. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL, J Bone Miner Res 2007 22 5 724 729 10.1359/jbmr.070207 17295604 (Pubitemid 351339101)
12. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, et al. Nature 2002 416 6882 744 749 10.1038/416744a 11961557 (Pubitemid 34429151)
13. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, et al. Nature 2000 408 6812 600 605 10.1038/35046102 11117749
14. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Qian WP, Sierra O, Pacifici R, Proc Natl Acad Sci USA 2003 100 18 10405 10410 10.1073/pnas.1533207100 12923292 (Pubitemid 37071891)
15. Transforming growth factor-beta1 to the bone. Janssens K, ten Dijke P, Janssens S, Van Hul W, Endocr Rev 2005 26 6 743 774 10.1210/er.2004-0001 15901668 (Pubitemid 41428537)
16. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. Kudo O, Fujikawa Y, Itonaga I, Sabokbar A, Torisu T, Athanasou NA, J Pathol 2002 198 2 220 227 10.1002/path.1190 12237882 (Pubitemid 35243880)
17. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H, Biochem Biophys Res Commun 2000 275 3 768 775 10.1006/bbrc.2000.3379 10973797
18. A rapid multiparameter approach to study factors that regulate osteoclastogenesis: demonstration of the combinatorial dominant effects of TNF-alpha and TGF-beta in RANKL-mediated osteoclastogenesis. Huang W, Drissi MH, O'Keefe RJ, Schwarz EM, Calcif Tissue Int 2003 73 6 584 593 10.1007/s00223-003-0059-8 14517717 (Pubitemid 37517804)
19. TGF-beta-induced SOCS3 expression augments TNF-alpha-induced osteoclast formation. Lovibond AC, Haque SJ, Chambers TJ, Fox SW, Biochem Biophys Res Commun 2003 309 4 762 767 10.1016/j.bbrc.2003.08.068 13679037 (Pubitemid 37122593)
20. IL-1 mediates TNF-induced osteoclastogenesis. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL, J Clin Invest 2005 115 2 282 290 15668736 (Pubitemid 40385470)
21. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Lubberts E, Cytokine 2008 41 2 84 91 10.1016/j.cyto.2007.09.014 18039580
22. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA, Bone 2003 32 1 1 7 10.1016/S8756-3282(02)00915-8 12584029 (Pubitemid 36173806)
23. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S, J Biol Chem 2008 283 17 11535 11540 10.1074/jbc.M607999200 18296709
24. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D, Cytokine Growth Factor Rev 2004 15 6 457 475 10.1016/j.cytogfr.2004.06.004 15561602 (Pubitemid 39550455)
25. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ, Endocrinology 2002 143 3 1108 1118 10.1210/en.143.3. 1108 11861538 (Pubitemid 34164059)
26. Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Itonaga I, Sabokbar A, Sun SG, Kudo O, Danks L, Ferguson D, Fujikawa Y, Athanasou NA, Bone 2004 34 1 57 64 10.1016/j.bone.2003.08.008 14751563 (Pubitemid 38142434)
27. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, et al. J Exp Med 2000 191 2 275 286 10.1084/jem.191.2.275 10637272 (Pubitemid 30060917)
28. The molecular understanding of osteoclast differentiation. Asagiri M, Takayanagi H, Bone 2007 40 2 251 264 10.1016/j.bone.2006.09.023 17098490 (Pubitemid 46054562)
29. Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis. Ralston SH, J Bone Miner Res 1994 9 6 883 890 8079663 (Pubitemid 24178071)
30. Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. D'Amelio P, Roato I, D'Amico L, Veneziano L, Suman E, Sassi F, Bisignano G, Ferracini R, Gargiulo G, Castoldi F, et al. Osteoporos Int 2010 22 11 2869 2877 21116815
31. Identification of differentially expressed genes between osteoarthritic and normal trabecular bone from the intertrochanteric region of the proximal femur using cDNA microarray analysis. Hopwood B, Gronthos S, Kuliwaba JS, Robey PG, Findlay DM, Fazzalari NL, Bone 2005 36 4 635 644 10.1016/j.bone.2005.02.003 15781004 (Pubitemid 40602257)
32. Enhanced expression of osteocalcin mRNA in human osteoarthritic trabecular bone of the proximal femur is associated with decreased expression of interleukin-6 and interleukin-11 mRNA. Kuliwaba JS, Findlay DM, Atkins GJ, Forwood MR, Fazzalari NL, J Bone Miner Res 2000 15 2 332 341 10703936 (Pubitemid 30095721)
33. Bone mineral density in osteoarthritis. Stewart A, Black AJ, Curr Opin Rheumatol 2000 12 5 464 467 10.1097/00002281-200009000-00021 10990188
34. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. Harris WH, J Bone Joint Surg Am 1969 51 4 737 755 5783851
35. Expression of bone resorption genes in osteoarthritis and in osteoporosis. Logar DB, Komadina R, Prezelj J, Ostanek B, Trost Z, Marc J, J Bone Miner Metab 2007 25 4 219 225 10.1007/s00774-007-0753-0 17593491 (Pubitemid 47012479)
36. Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation. Kamolmatyakul S, Chen W, Li YP, J Dent Res 2001 80 1 351 355 10.1177/00220345010800011001 11269728 (Pubitemid 32501337)
37. Relationship between serum RANKL and RANKL in bone. Findlay DM, Atkins GJ, Osteoporos Int 2011 22 10 2597 2602 10.1007/s00198-011-1740-9 21850548
38. Regulation of osteoclastogenesis and RANK expression by TGF-beta1. Yan T, Riggs BL, Boyle WJ, Khosla S, J Cell Biochem 2001 83 2 320 325 10.1002/jcb.1200 11573248 (Pubitemid 32896601)